Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Professor calls for better clinical trials of antivirals
Cats suffering from FIV and FeLV require special management and care.

Review looks at antiviral use in retrovirus-infected cats

A leading professor in small animal medicine is calling for better clinical trials of antivirals following publication of a review into their use in retrovirus-infected cats.

Professor Katrin Hartmann, head of the clinic of small animal medicine at the LMU University of Munich, Germany, says that more well-designed clinical trials would improve judgement on treatment efficacy and side effects.

Antiviral chemotherapy is of increasing interest in veterinary medicine, but is still not commonly used.  The review, published in the Journal of Feline Medicine and Surgery, examines current literature on antiviral chemotherapy in retrovirus-infected cats, focusing on drugs that are currently available on the market, and therefore could potentially be used in cats.

Concluding the review, Professor Hartmann writes: 'Unfortunately, the level of efficacy of antiviral chemotherapy is often poor and the duration of treatments used in clinical trials is often inappropriate for infections with such long clinical courses.

'Additionally, the degree of generalisability between experimental infections in cats kept under laboratory conditions and pet cats infected with field strains is unknown.
Therefore, it is very important that more well-designed double-blind, placebo-controlled trials using antivirals in naturally retrovirus-infected cats are undertaken to allow judgement on treatment efficacy and side effects of different antiviral compounds.'

Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) are among the most common infections affecting cats worldwide, but differ in their potential to cause disease. 
Cats suffering from FIV and FeLV require special management and care and, provided they receive this, can live for many years in good health.

In more severe cases, the advice is to consider incorporating antivirals into the treatment regime. Most antivirals used in cats are licensed for humans and are specifically intended for treatment of human immunodeficiency virus (HIV), based on the rationale that FIV and HIV are closely related.

FeLV is not as closely related to HIV, with the result that the available drugs have mostly been found to be less effective against this retrovirus.


Become a member or log in to add this story to your CPD history

Giraffe Conservation Foundation named BVNA’s charity of the year

News Story 1
 BVNA president Wendy Nevins has named The Giraffe Conservation Foundation as the association’s charity of the year for 2017/2018.

The Giraffe Conservation Foundation dedicates its work to a sustainable future for wild giraffe populations. Wendy Nevins said: ‘I have chosen the Giraffe Conservation Foundation for the BVNA Charity of the Year because I have always thought Giraffes were magnificent animals.

‘I also think it is important that we look at the wider issue of conservation and education across all species.’  

News Shorts
Scientists win award for openness in animal research

UK scientists have won an award for the 360ş Laboratory Animal Tours project, which offered the public an online, interactive tour of four research facilities that are usually restricted access.

The project won a public engagement award at the Understanding Animal Research (UAR) Openness Awards, which recognise UK research facilities for transparency on their use of animals in research, as well as innovation in communicating with the public.

The tour was created by the Pirbright Institute, the University of Oxford, the University of Bristol and MRC Harwell Institute.